Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 1.00 |
| ▸ | CNR1 | P21554 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16404249 | 0.88 | CNR2 (0.78) | CNR2CNR1LMNAHPGDALDH1A1 | |
| SCHEMBL16404210 | 0.84 | CNR2 (0.72) | CNR2CNR1LMNAHPGDALDH1A1 | |
| Adamantane SCHEMBL27759633 | 0.83 | CNR2 (0.70) | CNR2CNR1ALDH1A1KMT2A | |
| SCHEMBL3687439 | 0.80 | CNR2 (1.00) | CNR2CNR1HPGDALDH1A1FAAH | |
| SCHEMBL16404223 | 0.79 | CNR2 (0.65) | CNR2CNR1HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL27760017 | 0.78 | CNR2 (0.64) | CNR2CNR1ALDH1A1KMT2A | |
| SCHEMBL5998360 | 0.77 | CNR2 (0.63) | CNR2CNR1LMNAHPGDALDH1A1 | |
| SCHEMBL16404213 | 0.77 | CNR2 (1.00) | CNR2CNR1HPGDALDH1A1 | |
| SCHEMBL2033217 | 0.75 | CNR1 (0.65) | CNR2CNR1LMNAHPGDALDH1A1 | |
| SCHEMBL4963336 | 0.74 | CNR2 (0.80) | CNR2CNR1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| CN-101431994-A | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | CN | claimed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-8937184-B2 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2015-01-20 | — | — | US | disclosed |
| US-8937184-B2 | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators | ABBVIE B.V. (NL) | 2015-01-20 | — | — | US | disclosed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| CN-101431998-A | Containing CBxPharmaceutical compositions of cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | CN | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR2 1/4885CNR1 2/4885LMNA 2479/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR2 2/4885CNR1 1/4885LMNA 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.